- Study: Higher levels of sleep aid melatonin may reduce prostate cancer risk
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Appropriations bill to boost funding for Lupus Research Institute's education program
DEERFIELD, Ill. — Takeda Pharmaceutical has launched a new treatment for high blood pressure, the company said Friday.
Takeda announced the launch of Edarbi (azilsartan medoxomil), which the Food and Drug Administration approved on Feb. 25 as a once-daily pill for hypertension.
“Hypertension is a serious condition but typically does not have any symptoms, and many aren’t aware of the long-term impact hypertension has on cardiovascular health,” Takeda Pharmaceuticals North America executive medical director of medical and scientific affairs Paulos Berhanu said. “We are pleased to make available Edarbi, an important new treatment option for patients with hypertension and the healthcare professionals who treat them.”